DAT-230, a novel microtubule inhibitor, induced aberrant mitosis and apoptosis in SGC-7901 cells

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 2, 2013, Pages 193-201

  Qiao, Foxiao ^a   Zuo, Daiying ^a   Wang, Haifeng ^a   Li, Zengqiang ^a   Qi, Huan ^a   Zhang, Weige ^a   Wu, Yingliang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Microtubule inhibitor; SGC 7901; Xenograft

Indexed keywords

2 METHOXY 5 (2 (3,4,5 TRIMETHOXYPHENYL)THIOPHEN 3 YL)ANILINE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME C; DAT 230; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DEPOLYMERIZATION; DNA FRAGMENTATION; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; STOMACH CARCINOMA;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MITOSIS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOPHENES; TUBULIN MODULATORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874100833     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00321     Document Type: Article

References (41)

1. Nakamura T, Nakatsu N, Yoshida Y., Yamazaki K, Dan S, Sadahiro S., Makuuchi H, Yamori T. Identification of candidate genes determining chemosensitivity to anti-cancer drugs of gastric cancer cell lines. Biol. Pharm. Bull., 32, 1936-1939 (2009).
2. Ji YB, Qu ZY, Zou X. Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp. Toxicol. Pathol., 63, 69-78 (2011).
3. Li F, Awale S, Tezuka Y., Kadota S. Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship. Biol. Pharm. Bull., 32, 2075-2078 (2009).
4. Wilson L, Jordan MA Microtubule dynamics: taking aim at a moving target. Chem. Biol., 2, 569-573 (1995).
5. Fang L, Shen L, Fang Y., Hu Y, He Q, Yang B. MZ3 can induce G2/M-phase arrest and apoptosis in human leukemia cells. J. Cancer Res. Clin. Oncol., 134, 1337-1345 (2008).
6. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem., 266, 3987-3994 (1991).
7. Estève M.A., Carré M, Braguer D. Microtubules in apoptosis induction: are they necessary? Curr. Cancer Drug Targets, 7, 713-729 (2007).
8. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 4, 253-265 (2004).
9. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis, 8, 413-450 (2003).
10. Jordan A, Hadfield JA, Lawrence N.J., McGown AT Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev., 18, 259-296 (1998).
11. Pettit GR, Cragg GM, Singh SB Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod., 50, 386-391 (1987).
12. Pettit GR, Singh SB, Boyd M.R., Hamel E., Pettit RK, Schmidt JM, Hogan F. Antineoplastic agents. 291. Isolation and synthesis of com-bretastatins A-4, A-5, and A-6(1a). J. Med. Chem., 38, 1666-1672 (1995).
13. Islam MN, Iskander MN Microtubulin binding sites as target for developing anticancer agents. Mini Rev. Med. Chem., 4, 1077-1104 (2004).
14. Wehbe H, Kearney CM, Pinney KG Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res., 25 (6B), 3865-3870 (2005).
15. Zweifel M, Jayson GC, Reed N.S., Osborne R., Hassan B, Ledermann J, Shreeves G. Phase II trial of combretastatin A4 phosphate, car-boplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann. L. Oncol., 22, 2036-2041 (2011).
16. Kerr DJ, Hamel E, Jung M.K., Flynn BL The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4. Bioorg. Med. Chem., 15, 3290-3298 (2007).
17. Lee L, Davis R, Vanderham J., Hills P, Mackay H, Brown T., Mooberry SL, Lee M. 1,2,3,4-Tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4. Eur. J. Med. Chem., 43, 2011-2015 (2008).
18. Johnson M, Younglove B, Lee L., LeBlanc R, Holt H Jr, Hills P, Mackay H, Brown T., Mooberry SL, Lee M. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg. Med. Chem. Lett., 17, 5897-5901 (2007).
19. Marrelli M, Conforti F, Statti G.A., Cachet X., Michel S, Tillequin F, Menichini F. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4. Curr. Med. Chem., 18, 3035-3081 (2011).
20. Qiao F, Zuo D, Shen X., Qi H, Wang H, Zhang W., Wu Y. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080. Cancer Chemother. Pharmacol., 70, 259-270 (2012).
21. Li D, Wu LJ, Tashiro S, Onodera S., Ikejima T. oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J. Pharmacol. Sci., 103, 56-66 (2007).
22. Saris NE, Teplova V V, odinokova I V, Azarashvily TS Interference of calmidazolium with measurement of mitochondrial membrane potential using the tetraphenylphosphonium electrode or the fluorescent probe rhodamine 123. Anal. Biochem., 328, 109-112 (2004).
23. Andrews NC, Faller DV A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19, 2499 (1991).
24. Toyoshima F, Moriguchi T, Wada A., Fukuda M, Nishida E. Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J., 17, 2728-2735 (1998).
25. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ., 9, 1287-1293 (2002).
26. Chen YC, Lu PH, Pan S.L., Teng CM, Kuo SC, Lin TP, Ho Y.F., Huang YC, Guh JH Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Biochem. Pharmacol., 74, 10-19 (2007).
27. Chang WL, Chang CS, Chiang P.C., Ho YF, Liu JF, Chang KW, Guh JH 2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase. Br. J. Pharmacol., 160, 1677-1689 (2010).
28. Suen DF, Norris KL, Youle RJ Mitochondrial dynamics and apo-ptosis. Genes Dev., 22, 1577-1590 (2008).
29. Von Ahsen O., Waterhouse NJ, Kuwana T, Newmeyer D.D., Green DR The 'harmless' release of cytochrome c. Cell Death Differ., 7, 1192-1199 (2000).
30. Pettit GR, Singh SB, Hamel E, Lin C.M., Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia, 45, 209-211 (1989).
31. Cenciarelli C, Tanzarella C, Vitale I., Pisano C, Crateri P, Meschini S., Arancia G, Antoccia A. The tubulin-depolymerising agent com-bretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis, 13, 659-669 (2008).
32. Wang TH, Wang HS, Soong YK Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer, 88, 2619-2628 (2000).
33. Meijer L, Azzi L, Wang J Y. Cyclin B targets p34cdc2 for tyrosine phosphorylation. EMBO J., 10, 1545-1554 (1991).
34. Jin P, Hardy S, Morgan DO Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J. Cell Biol., 141, 875-885 (1998).
35. Wang LG, Liu XM, Kreis W, Budman DR The effect of antimi-crotubule agents on signal transduction pathways of apoptosis: are view. Cancer Chemother. Pharmacol., 44, 355-361 (1999).
36. Smits VA, Medema RH Checking out the G(2)/M transition. Biochim. Biophys. Acta, 1519, 1-12 (2001).
37. Zamzami N, Brenner C, Marzo I., Susin SA, Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene, 16, 2265-2282 (1998).
38. Liu X, Kim CN, Yang J, Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86, 147-157 (1996).
39. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemo-resistance in hematologic malignancies. Semin. Hematol., 34 (Suppl. 5), 9-19 (1997).
40. Zou H, Li Y, Liu X., Wang X. An APAF-1-cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem., 274, 11549-11556 (1999).
41. Pathan N, Aime-Sempe C, Kitada S., Haldar S, Reed JC Microtubule- targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia, 3, 70-79 (2001).